Luye Pharma's two core products, Lipusu®, an innovative paclitaxel liposome formulation, and CMNa®, sodium glycididazole for injection, a Class I New Chemical Drug, have been recommended by the China Guidelines on Radiotherapy for Esophageal Cancer (2019). The guidelines were jointly developed by three authoritative academic institutions, the Chinese Association for Therapeutic Radiation Oncologists (branch association of the Chinese Medical Doctor Association), the Chinese Society of Radiation Oncology (branch association of the Chinese Medical Association), and the Society of Radiation Therapy of the China Anti-Cancer Association.
Esophageal cancer is a commonly seen digestive tract cancer with poor prognosis and is a serious threat to human health. China has a high incidence of esophageal cancer, with more than 50% of the world’s sufferers living in the nation. When compared to patients in Europe and the U.S., esophageal cancer patients in China exhibit large differences in etiology, pathological types and high-incidence sites, among others, resulting in the guidelines for esophageal cancer radiotherapy in Europe and the United States not fully meeting China’s clinical needs. With the aim of addressing this problem and promoting standardized treatment, a group of well-known Chinese experts co-authored the "China Guidelines on Radiotherapy for Esophageal Cancer (2019)" , which cover the whole process of radiotherapy for the disease.
Paclitaxel Liposome recommended as the preferred medication for multiple chemo/radio therapies
The China Guidelines on Radiotherapy for Esophageal Cancer (2019) suggest that paclitaxel liposome is an alternative to paclitaxel used in conventional chemotherapy and recommend that paclitaxel (paclitaxel liposome) in combination with other drugs as the preferred option for Neoadjuvant chemotherapy/chemoradiotherapy, Radical chemoradiotherapy, Palliative chemoradiotherapy, Adjuvant radiotherapy/chemoradiotherapy and other treatments.
Paclitaxel Liposome - Lipusu® is an innovative paclitaxel liposome formulation with a liposome delivery system and targeted drug delivery technology developed by Luye Pharma. The company holds patents on the composition and formulation process for the drug. Instead of using Cremophor EL mixed with anhydrous ethanol as a solvent, which may cause severe allergic reactions, Lipusu® encapsulates the water-insoluble paclitaxel into the liposome bilayer, improving its safety in clinical use by reducing adverse reactions while maintaining its specific efficacy. In addition to having been recommended in China by the Guidelines on Radiotherapy for Esophageal Cancer, Lipusu® has also been recommended as a first-line drug by the CSCO Primary Lung Cancer Treatment Guidelines and included in the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Gynecologic Malignancies.
Sodium Glycidazole for Injection is recommended for combined radiotherapy and concurrent chemoradiotherapy
Based on sufficient data from evidence-based medical research, the Guidelines point out that sodium glycididazole for injection is a radiosensitizer with high efficacy and low-toxicity. It is recommended to be used in combination with radiotherapy and concurrent chemoradiotherapy for the treatment of esophageal cancer.
Sodium Glycidazole for Injection - CMNa® is a Class I New Chemical Drug developed independently by Luye Pharma, indicated for use in combination with radiotherapy for certain solid tumours. According to the data from China’s National Medical Products Administration, as of the first half of 2019, CMNA® is the only sodium glycididazole product currently marketed in China. In addition, an independent third-party study shows that using CMNA® to treat certain types of cancer, such as esophageal cancer, can increase the rate of complete or partial response and reduce the overall cost of treatment. The short-term efficacy and long-term survival indicators of CMNA® are also superior to radiotherapy alone. Short-term efficacy indicators include CR (complete response) ratio, CR+PR (partial response) ratio, while the long-term survival indicators include the 3 or 5-year survival rate, rate of no recurrence and rate of no increase in metastasis.
A Luye Pharma Group management representative commented, “As two of the company's core products in the oncology therapeutic area, Lipusu® and CMNa® have been widely recognized by physicians and patients over their long-term clinical application. Following their recommendation by the Guidelines we can expect to see wider application of these two products among their relevant indications, improved access for patients and more patients receiving the benefits of these medicines.”
Luye Pharma's two core products, Lipusu®, an innovative paclitaxel liposome formulation, and CMNa®, sodium glycididazole for injection, a Class I New Chemical Drug, have been recommended by the China Guidelines on Radiotherapy for Esophageal Cancer (2019). The guidelines were jointly developed by three authoritative academic institutions, the Chinese Association for Therapeutic Radiation Oncologists (branch association of the Chinese Medical Doctor Association), the Chinese Society of Radiation Oncology (branch association of the Chinese Medical Association), and the Society of Radiation Therapy of the China Anti-Cancer Association.
Esophageal cancer is a commonly seen digestive tract cancer with poor prognosis and is a serious threat to human health. China has a high incidence of esophageal cancer, with more than 50% of the world’s sufferers living in the nation. When compared to patients in Europe and the U.S., esophageal cancer patients in China exhibit large differences in etiology, pathological types and high-incidence sites, among others, resulting in the guidelines for esophageal cancer radiotherapy in Europe and the United States not fully meeting China’s clinical needs. With the aim of addressing this problem and promoting standardized treatment, a group of well-known Chinese experts co-authored the "China Guidelines on Radiotherapy for Esophageal Cancer (2019)" , which cover the whole process of radiotherapy for the disease.
Paclitaxel Liposome recommended as the preferred medication for multiple chemo/radio therapies
The China Guidelines on Radiotherapy for Esophageal Cancer (2019) suggest that paclitaxel liposome is an alternative to paclitaxel used in conventional chemotherapy and recommend that paclitaxel (paclitaxel liposome) in combination with other drugs as the preferred option for Neoadjuvant chemotherapy/chemoradiotherapy, Radical chemoradiotherapy, Palliative chemoradiotherapy, Adjuvant radiotherapy/chemoradiotherapy and other treatments.
Paclitaxel Liposome - Lipusu® is an innovative paclitaxel liposome formulation with a liposome delivery system and targeted drug delivery technology developed by Luye Pharma. The company holds patents on the composition and formulation process for the drug. Instead of using Cremophor EL mixed with anhydrous ethanol as a solvent, which may cause severe allergic reactions, Lipusu® encapsulates the water-insoluble paclitaxel into the liposome bilayer, improving its safety in clinical use by reducing adverse reactions while maintaining its specific efficacy. In addition to having been recommended in China by the Guidelines on Radiotherapy for Esophageal Cancer, Lipusu® has also been recommended as a first-line drug by the CSCO Primary Lung Cancer Treatment Guidelines and included in the Expert Consensus on the Clinical Application of Taxanes for the Treatment of Gynecologic Malignancies.
Sodium Glycidazole for Injection is recommended for combined radiotherapy and concurrent chemoradiotherapy
Based on sufficient data from evidence-based medical research, the Guidelines point out that sodium glycididazole for injection is a radiosensitizer with high efficacy and low-toxicity. It is recommended to be used in combination with radiotherapy and concurrent chemoradiotherapy for the treatment of esophageal cancer.
Sodium Glycidazole for Injection - CMNa® is a Class I New Chemical Drug developed independently by Luye Pharma, indicated for use in combination with radiotherapy for certain solid tumours. According to the data from China’s National Medical Products Administration, as of the first half of 2019, CMNA® is the only sodium glycididazole product currently marketed in China. In addition, an independent third-party study shows that using CMNA® to treat certain types of cancer, such as esophageal cancer, can increase the rate of complete or partial response and reduce the overall cost of treatment. The short-term efficacy and long-term survival indicators of CMNA® are also superior to radiotherapy alone. Short-term efficacy indicators include CR (complete response) ratio, CR+PR (partial response) ratio, while the long-term survival indicators include the 3 or 5-year survival rate, rate of no recurrence and rate of no increase in metastasis.
A Luye Pharma Group management representative commented, “As two of the company's core products in the oncology therapeutic area, Lipusu® and CMNa® have been widely recognized by physicians and patients over their long-term clinical application. Following their recommendation by the Guidelines we can expect to see wider application of these two products among their relevant indications, improved access for patients and more patients receiving the benefits of these medicines.”
